A correlation between pCR rates and the expression of PD-L1 (34, 35) and TILs (35) was seen in those trials across the spectrum of ER-positive tumors, which suggests the potential of a biologically informed, response-oriented subtyping of BC (67). The gene discussed is ESR1; the disease is breast cancer.